Pumped by an ear­ly glimpse of ef­fi­ca­cy, Newron charts a piv­otal course for schiz­o­phre­nia drug

Just a few days af­ter Newron fi­nal­ly land­ed an FDA ap­proval for Parkin­son’s add-on ther­a­py Xada­go af­ter a 4-year reg­u­la­to­ry odyssey, the biotech is back with a snap­shot of ear­ly da­ta on a new treat­ment for schiz­o­phre­nia. And while they were able to pull out pos­i­tive da­ta from the Phase IIa study of eve­namide, in­ves­ti­ga­tors plan to make some sig­nif­i­cant changes to the next study that could pro­vide more plain­ly promis­ing piv­otal re­sults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.